Day: November 21, 2024

TORONTO, Nov. 21, 2024 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, announces that it has signed Blue Unmanned Aerial Systems (UAS) and US National Defense Authorization Act (NDAA) compliant partner agreements for its supply chain in order to sell its ZenaDrone 1000 AI drone solutions to US Defense branches and to NATO forces. Through its subsidiary ZenaDrone, the Company recently participated in a Taiwan Trade Mission organized by the Arizona Commerce Authority (ACA) that directly resulted in these partnerships. ZenaTech can now confirm that all ZenaDrone’s electrical components and supply chain will comply with NDAA standards. ZenaDrone previously completed...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –China controls ~80%+ of global tungsten extraction & processing and has recently announced measures to curb its supply into North America There are no domestic tungsten producers in the United States Demesne is assessing the potential for the IMA Mine to play vital role in establishing domestic tungsten supply and onshoring production capabilitiesVancouver, BC, Nov. 21, 2024 (GLOBE NEWSWIRE) — Demesne Resources Ltd. (CSE:DEME) (OTCQB:DEMRF) (“Demesne” or the “Company”), in response to China’s intention to restrict tungsten exports, plans to update and define the historical resources of the past producing, Idaho-based IMA Mine tungsten-molybdenum property, while exploring the opportunity to bring onshore tungsten mining and production...

CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and clinically relevant longitudinal biomarkers AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data demonstrating the utility of the CNSide CSF Assay Platform in identifying mutations of key biomarkers in the CSF and their implications in treatment selection for LM. The data will be presented at the 2024 Society for NeuroOncology (SNO) Annual Meeting November 21-24 in Houston, Texas.   “The data from CNSide suggests that biomarker mutation profiles in LM are dynamic, offering valuable insights for treatment...

HERZLIYA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and maximizing loyalty, today announced that it will launch its end-to-end automated self-service payment solution across El Salvador, enabling consumers to make secure cashless payments at automated machines with VPOS Touch™ devices. Nayax will work with trusted local partners to enable Salvadoran operators to join our global community of more than 90,000 customers, improving their customer experience with flexible, cashless payments and advanced loyalty programs. As an initial stage, Nayax will install hundreds of VPOS Touch™ devices in diverse locations across El Salvador, including shopping malls, office...

TORONTO, Nov. 21, 2024 (GLOBE NEWSWIRE) — Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products, announced today that the Company’s third quarter 2024 financial results will be released after market close on Thursday, November 28, 2024.  The Company will host a conference call to discuss these results and provide an operational update and recap of achievements on Friday, November 29, 2024. Conference Call Details: CEO and Executive Chairman, George Scorsis and CFO, Vaani Maharaj will host the conference call. Following the opening remarks, management will be available to answer questions.Date: Friday, November 29, 2024Time: 10:00am ETToll Free Number: Canada/USA: 1-844-763-8274  International...

-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 –First participant dosing anticipated in the first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026 CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that it has received approval from the Australian Bellberry Human Research Ethics Committee (HREC) and clearance from the Australian Therapeutic Goods Administration (TGA) to initiate a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD). “We...

Roseland, NJ, Nov. 21, 2024 (GLOBE NEWSWIRE) — Gaxos.ai Inc. (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that the Company successfully integrated Suno AI and ElevenLabs into their artificial intelligence solution for game developers and publishers, Gaxos Labs. “We are pleased to welcome Suno AI and ElevenLabs into our Gaxos Labs ecosystem,” said Vadim Mats, CEO of Gaxos. “As we continue on our path to becoming an all-in-one artificial intelligence solution for game developers and publishers, we will add other AI tools to make our product more robust and invaluable.” Suno and ElevenLabs offers users the ability to generate sound clips, generate lyrics from prompts, generate sound effects, and many more. For more information,...

WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.3350 per share of common stock, at a combined public offering price of $0.89 per share of common stock and...

Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing value NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit” or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company’s lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders. This approval follows the recent patent grant in Australia, highlighting Conduit’s continued progress in safeguarding its intellectual property portfolio for future out-licensing opportunities. “This approval represents another significant milestone in our efforts to maximize...

OKLAHOMA CITY, Nov. 21, 2024 (GLOBE NEWSWIRE) — Expand Energy Corporation (NASDAQ: EXE) (“Expand Energy”) announced today that the expiration date for its previously announced cash tender offer (the “Tender Offer”) for any and all of its outstanding 5.500% Senior Notes due 2026 (the “2026 Notes”) has been amended to 5:00 p.m., New York City time, on November 27, 2024, unless extended or earlier terminated (such time and date, as the same may be extended, the “Expiration Time”).  The Tender Offer is being made pursuant to an Offer to Purchase, dated November 20, 2024, as amended on November 21, 2024  (as may be further amended or supplemented from time to time, the “Offer to Purchase”) and the related Notice of Guaranteed Delivery. The Guaranteed Delivery Time (as defined in the Offer to Purchase) has also been amended to 5:00 p.m.,...